ClinicalTrials.gg
CompletedNCT07640867Updated Jun 11, 2026

RCI001 Eye Drops 0.25% in Healthy Adult Male Participants

A Phase 1 interventional study of RCI001 Eye Drops 0.25% and Placebo Eye Drops in Dry Eye, sponsored by Rudacure. Completed at 1 site in South Korea. Open to male participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Rudacure · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Oct 2024, registered May 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.

Enrollment
41st of 52
40 · median 99
Started
2024
with 1 other
Phase 1
6 of 58
none open now
Registered
56th of 58
by date

Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 41st largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 1, and was the 56th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of RCI001 eye drops 0.25% in healthy adult male participants. Pharmacokinetics means how the study drug is absorbed, distributed, and eliminated from the body over time.

Participants who meet the study requirements will be randomly assigned to receive either RCI001 eye drops 0.25% or placebo eye drops. The study treatment will be administered to the left eye according to the assigned dosing schedule. The study includes single-dose administration schedules and multiple-dose administration schedules for up to 15 days.

The study will monitor safety and tolerability through adverse event assessments, vital signs, physical examinations, electrocardiograms, laboratory tests, eye symptom assessments, and ophthalmic examinations. Blood samples will be collected at scheduled time points to measure the concentration of RCI001 in the blood.

Approximately 40 healthy adult male participants are planned to take part in this study.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • RCI001 Eye Drops
  • Dry Eye Diseases
  • Phase 1 Clinical Trial
  • Rudacure
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male volunteers aged 19 to 50 years at screening.
  2. Body weight of 50.0 kg to 90.0 kg and (BMI) of 18.5 kg/m2 to 29.9 kg/m2 at screening.
  3. Participants who have received sufficient explanation about the study, fully understand the study, voluntarily decide to participate, and provide written to comply with study requirements.
  4. Participants who are considered eligible for this study by the investigator based on physical examination, clinical laboratory tests, medical interview, and other screening assessments.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a current or past history of disease in the hepatobiliary system, kidney, nervous system, immune system, respiratory system, gastrointestinal system, endocrine system, hematologic or oncologic system, cardiovascular system, urinary system, or psychiatric system, including but not limited to severe hepatic impairment, viral hepatitis, severe renal impairment, heart failure, Torsade de pointes, mood disorder, or obsessive-compulsive disorder.
  2. Participation in another clinical trial, including a bioequivalence study, and administration of an product within 6 months before the first planned administration of the investigational product.
  3. Current smoker who cannot stop smoking during the study period. Participants who stopped smoking at least 3 months before the first planned administration of the investigational product may be eligible.
  4. Consumption of grapefruit, grapefruit juice, or grapefruit-containing foods from 3 days before the first planned administration of the investigational product until the end of the study, or inability to abstain from grapefruit-containing foods and beverages during this period.
  5. Participants who are considered unsuitable for participation in the study by the investigator for any other reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    RCI001 Eye Drops 0.25%, Single-Day Administration, Once Daily

    Drug: RCI001 Eye Drops 0.25%

  • Placebo comparator
    Placebo Eye Drops, Single-Day Administration, Once Daily

    Drug: Placebo Eye Drops

  • Experimental
    RCI001 Eye Drops 0.25%, Single-Day Administration, Twice Daily

    Drug: RCI001 Eye Drops 0.25%

  • Placebo comparator
    Placebo Eye Drops, Single-Day Administration, Twice Daily

    Drug: Placebo Eye Drops

  • Experimental
    RCI001 Eye Drops 0.25%, Single-Day Administration, Four Times Daily

    Drug: RCI001 Eye Drops 0.25%

  • Placebo comparator
    Placebo Eye Drops, Single-Day Administration, Four Times Daily

    Drug: Placebo Eye Drops

  • Experimental
    RCI001 Eye Drops 0.25%, Multiple-Day Administration, Twice Daily

    Drug: RCI001 Eye Drops 0.25%

  • Placebo comparator
    Placebo Eye Drops, Multiple-Day Administration, Twice Daily

    Drug: Placebo Eye Drops

  • Experimental
    RCI001 Eye Drops 0.25%, Multiple-Day Administration, Four Times Daily

    Drug: RCI001 Eye Drops 0.25%

  • Placebo comparator
    Placebo Eye Drops, Multiple-Day Administration, Four Times Daily

    Drug: Placebo Eye Drops

Interventions

  • DrugRCI001 Eye Drops 0.25%

    RCI001 eye drops 0.25% administered to the left eye according to the assigned dosing schedule.

    Also known as: RCI001

  • DrugPlacebo Eye Drops

    Matching placebo eye drops administered to the left eye according to the assigned dosing schedule.

    Also known as: Matching placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The number and percentage of participants with adverse events will be summarized by treatment group. Adverse events will be assessed for seriousness, severity, relationship to the study drug, action taken, outcome, and whether they are treatment-emergent adverse events.

    Time frame: From informed consent through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts

  2. Number of Participants With Clinically Significant Abnormalities in Safety Assessments

    Safety assessments will include vital signs, physical examinations, 12-lead electrocardiograms, clinical laboratory tests, ocular symptom assessments, and ophthalmic examinations. Clinically significant abnormalities will be summarized by treatment group.

    Time frame: From baseline through the post-study visit, up to Day 18 for single-administration cohorts and up to Day 32 for multiple-administration cohorts

Secondary outcomes

  1. Time to Maximum Plasma Concentration (Tmax) of RCI001 After Single Administration

    Tmax will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11

  2. Maximum Observed Plasma Concentration (Cmax) of RCI001 After Single Administration

    Cmax will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 25

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of RCI001 After Single Administration

    AUClast will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11.

  4. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of RCI001 After Single Administration

    AUCinf will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11.

  5. Terminal Elimination Half-Life (t1/2) of RCI001 After Single Administration

    Terminal elimination half-life will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11.

  6. Apparent Clearance (CL/F) of RCI001 After Single Administration

    CL/F will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11.

  7. Apparent Volume of Distribution (Vz/F) of RCI001 After Single Administration

    Vz/F will be calculated from plasma RCI001 concentration-time data after single administration.

    Time frame: Predose on Day -1 through Day 11.

  8. Time to Maximum Plasma Concentration at Steady State (Tmax,ss) of RCI001 After Multiple Administration

    Tmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  9. Maximum Observed Plasma Concentration at Steady State (Cmax,ss) of RCI001 After Multiple Administration

    Cmax,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  10. Minimum Observed Plasma Concentration at Steady State (Cmin,ss) of RCI001 After Multiple Administration

    Cmin,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  11. Average Plasma Concentration at Steady State (Cavg,ss) of RCI001 After Multiple Administration

    Cavg,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  12. Trough Plasma Concentration (Ctrough) of RCI001 After Multiple Administration

    Ctrough will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  13. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval at Steady State (AUCtau,ss) of RCI001 After Multiple Administration

    AUCtau,ss will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  14. Terminal Elimination Half-Life at Steady State (t1/2,ss) of RCI001 After Multiple Administration

    Terminal elimination half-life at steady state will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  15. Apparent Clearance at Steady State (CLss/F) of RCI001 After Multiple Administration

    CLss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  16. Apparent Volume of Distribution at Steady State (Vz,ss/F) of RCI001 After Multiple Administration

    Vz,ss/F will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

  17. Peak-to-Trough Fluctuation (PTF) of RCI001 After Multiple Administration

    PTF will be calculated from plasma RCI001 concentration-time data after multiple administration.

    Time frame: Predose on Day -1 through Day 25.

07

Study locations

1 site
  • Seoul national unversity hospital
    Seoul, South Korea
08

References and documents

Publications

  • Im ST, Kim HY, Yoon JY, Oh JY, Kim MK, Chung MH, Paik HJ, Kim DH. Therapeutic Effects of Topical 8-Oxo-2'-deoxyguanosine on Ethanol-Induced Ocular Chemical Injury Models. Cornea. 2018 Oct;37(10):1311-1317. doi: 10.1097/ICO.0000000000001671. PubMed 29923862 ↗
  • Kim DH, Im ST, Yoon JY, Kim S, Kim MK, Chung MH, Park CK. Comparison of therapeutic effects between topical 8-oxo-2'-deoxyguanosine and corticosteroid in ocular alkali burn model. Sci Rep. 2021 Mar 25;11(1):6909. doi: 10.1038/s41598-021-86440-7. PubMed 33767351 ↗
  • Kim SH, Ku YA, Yoo C, Kim YH, Kim DH. Comparison of RCI001 and corticosteroid on the effects on intraocular pressure in mice. Front Med (Lausanne). 2023 Oct 9;10:1256569. doi: 10.3389/fmed.2023.1256569. eCollection 2023. PubMed 37877019 ↗
  • Jung YH, Ku YA, Moon J, Kim S, Ryu JS, Yoon CH, Chung MH, Kim YH, Kim MK, Kim DH. Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model. Eye Vis (Lond). 2024 Jun 1;11(1):19. doi: 10.1186/s40662-024-00388-z. PubMed 38822444 ↗
  • Kim S, Jang YW, Ku YA, Shin Y, Rahman MM, Chung MH, Kim YH, Kim DH. Investigating the Anti-Inflammatory Effects of RCI001 for Treating Ocular Surface Diseases: Insight Into the Mechanism of Action. Front Immunol. 2022 Mar 24;13:850287. doi: 10.3389/fimmu.2022.850287. eCollection 2022. PubMed 35401555 ↗
  • Chung H, Ha Y, Kim YH, Kim DH, Shin D. Ocular Distribution and Pharmacokinetics of 8-Oxo-2'-Deoxyguanosine: A Novel Therapeutic Candidate of Ocular Surface Diseases. J Ocul Pharmacol Ther. 2022 Oct;38(8):561-566. doi: 10.1089/jop.2022.0054. PubMed 36288559 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers. The study has been completed and the results are planned to be submitted for publication. De-identified individual participant-level data are not planned for external sharing due to participant confidentiality, informed consent, regulatory, legal, and proprietary considerations related to the investigational drug product. Aggregate results may be disclosed through ClinicalTrials.gov, scientific publication, and/or regulatory submissions, as applicable.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Aug 2025, 10 months.

Of 34 phase 1 interventional studies under Dry Eye Syndromes, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 10 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 11, 2026
StartActual
Oct 28, 2024
Primary completionActual
Aug 29, 2025
CompletionActual
Sep 20, 2025
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07640867
Lead sponsor
Rudacure
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Oct 28, 2024
Primary completion
Aug 29, 2025
Completion
Sep 20, 2025
Last update
Jun 11, 2026

Study contacts

SeungHwan Lee, M.D., Ph.D.
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion